XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome

By S. Rigaud, M. Fondanèche, N. Lambert, V. Mateo, Pauline Soulas, L. Galicier, F. Deist, F. Rieux-Laucat, P. Revy, A. Fischer and 2 more. Nature, 2006

688 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/c4c094aeb77b64cec921765d810fa873f2fdf719

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. M. Gyrd-Hansen
2. P. Meier

Citations in the corpus

• Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. (2011, neutral): “Mean/median age, mo (range) 24/8 (0-184) 16/2 (0-145) (2*) 23/4 (0-137) 15/4 (0-150) (2*) 51/24 (2-184) (1*)”
• IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancer (2010, background): “Such regimens will also have to take into account that inhibition of XIAP may not only render cancer cells more susceptible to apoptosis, and limit inflammatory signalling, but also perturb natural killer T cell homeostasis and contribute to X-linked lymphoproliferative syndrom”